Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay)

J. Rajnay, L. Kopper, K. Lapis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chemotherapeutic response to two squamous cell carcinoma xenograft lines (established from the primary and metastatic lesion of a tongue carcinoma) was studied using SC and SRC assays (as well as immunocompetent and -suppressed recipients in the latter assay). The two assays provided similar ranking of drugs, in the sence that in each instances two of the three (cyclophosphamide, 5-fluorouracil, vinblastine) most active agents were identical. The host response in immunocompetent recipients supports the need for histology to prove the proper quality of the implanted tumor tissue in order to be used for drug evaluation.

Original languageEnglish
Pages (from-to)307-311
Number of pages5
JournalOncology
Volume44
Issue number5
Publication statusPublished - 1987

Fingerprint

Subrenal Capsule Assay
Drug Evaluation
Vinblastine
Tongue
Heterografts
Fluorouracil
Cyclophosphamide
Squamous Cell Carcinoma
Histology
Carcinoma
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay). / Rajnay, J.; Kopper, L.; Lapis, K.

In: Oncology, Vol. 44, No. 5, 1987, p. 307-311.

Research output: Contribution to journalArticle

@article{a03fba1a78534fcbaac9ec418e83f322,
title = "Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay)",
abstract = "Chemotherapeutic response to two squamous cell carcinoma xenograft lines (established from the primary and metastatic lesion of a tongue carcinoma) was studied using SC and SRC assays (as well as immunocompetent and -suppressed recipients in the latter assay). The two assays provided similar ranking of drugs, in the sence that in each instances two of the three (cyclophosphamide, 5-fluorouracil, vinblastine) most active agents were identical. The host response in immunocompetent recipients supports the need for histology to prove the proper quality of the implanted tumor tissue in order to be used for drug evaluation.",
author = "J. Rajnay and L. Kopper and K. Lapis",
year = "1987",
language = "English",
volume = "44",
pages = "307--311",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay)

AU - Rajnay, J.

AU - Kopper, L.

AU - Lapis, K.

PY - 1987

Y1 - 1987

N2 - Chemotherapeutic response to two squamous cell carcinoma xenograft lines (established from the primary and metastatic lesion of a tongue carcinoma) was studied using SC and SRC assays (as well as immunocompetent and -suppressed recipients in the latter assay). The two assays provided similar ranking of drugs, in the sence that in each instances two of the three (cyclophosphamide, 5-fluorouracil, vinblastine) most active agents were identical. The host response in immunocompetent recipients supports the need for histology to prove the proper quality of the implanted tumor tissue in order to be used for drug evaluation.

AB - Chemotherapeutic response to two squamous cell carcinoma xenograft lines (established from the primary and metastatic lesion of a tongue carcinoma) was studied using SC and SRC assays (as well as immunocompetent and -suppressed recipients in the latter assay). The two assays provided similar ranking of drugs, in the sence that in each instances two of the three (cyclophosphamide, 5-fluorouracil, vinblastine) most active agents were identical. The host response in immunocompetent recipients supports the need for histology to prove the proper quality of the implanted tumor tissue in order to be used for drug evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0023182825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023182825&partnerID=8YFLogxK

M3 - Article

C2 - 3670798

AN - SCOPUS:0023182825

VL - 44

SP - 307

EP - 311

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -